NCT02158702View on ClinicalTrials.gov

Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib

PHASE2UnknownINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

February 28, 2018

Study Completion Date

November 30, 2018

Conditions
Multiple MyelomaRelapse After Use of Lenalidomide and Bortezomib
Interventions
DRUG

Pomalidomide and Dexamethasone

Pomalidomide will be given at 4mg once daily for 21 days in a 28-day cycle. Dexamethasone will be given at a dose of 40mg orally once a week for 4 weeks (D1,8,15,22).

Trial Locations (2)

119074

National University Hospital, Singapore

Unknown

Singapore General Hospital, Singapore

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

National University Hospital, Singapore

OTHER

NCT02158702 - Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib | Biotech Hunter | Biotech Hunter